Gene Therapy Approaches to Replace or Restore Dystrophin PF-06939926 – Kasia Lobello, MD (Pfizer, Inc.) RGX-202 – Jahannaz Dastgir, DO (REGENXBIO) scAAV9.U7-ACCA – Kevin Flanigan, MD (Nationwide Children’s Hospital) SGT-001 – Carl Morris, PhD (Solid Biosciences) SRP-9001 – Teji Singh, MD (Sarepta Therapeutics) 4 years ago 2022 PPMD Annual Conference,Conferences & Meetings You may also like 10:23 Cumberland Pharmaceuticals 6 years ago Conferences & Meetings,In the Pipeline: Downstream Targets 7:11 Epirium Bio 6 years ago Conferences & Meetings,In the Pipeline: Downstream Targets 18:36 Sarepta Therapeutics (RNA Targeted Therapies) 6 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 11:46 NS Pharma 6 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 11:20 PTC Therapeutics (Ataluren) 6 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 15:10 Daiichi-Sankyo 6 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 20:43 ReveraGen BioPharma 6 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 12:20 Catabasis 6 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation «1…2324252627…29»Page 25 of 29